TLR1 Activators
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pam3Cys-Ser-(Lys)4 trihydrochloride | 112208-04-5 | sc-202271 | 2 mg | $431.00 | ||
Pam3Cys-Ser-(Lys)4 trihydrochloride is a potent TLR1 agonist that engages Toll-like receptors with high specificity, triggering robust immune signaling pathways. Its unique peptide structure enhances binding affinity, leading to effective receptor dimerization and downstream activation of NF-kB and MAPK pathways. The compound exhibits remarkable solubility and stability, which influences its kinetic profile and interaction with immune cells, ultimately shaping the inflammatory response. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
Pam3CSK4 is a synthetic triacylated lipopeptide that mimics the acylated amino terminus of bacterial lipoproteins and strongly activates the TLR1 and TLR2 pathway. Activation of these receptors by Pam3CSK4 leads to NF-κB activation and pro-inflammatory cytokine production, thus enhancing TLR1 function. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
Lipopolysaccharide (LPS) is a potent stimulator of TLR4, which can form a complex with MD-2 and CD14 leading to NF-κB activation. This event can indirectly enhance TLR1 activity by promoting the formation of TLR1/2 heterodimers, which are more responsive to their ligands. | ||||||
Polyinosinic-polycytidylic acid potassium salt | 31852-29-6 | sc-202767 | 5 mg | $198.00 | ||
Poly(I:C) is a synthetic analog of double-stranded RNA that activates TLR3. Activation of TLR3 triggers a signaling cascade that can indirectly enhance TLR1 activity by inducing the release of pro-inflammatory cytokines that upregulate the expression of TLR1/2 heterodimers. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod is a TLR7 agonist that stimulates the release of pro-inflammatory cytokines. This event can indirectly enhance TLR1 activity by increasing the expression of TLR1/2 heterodimers and their responsiveness to their ligands. | ||||||
Zymosan | 9010-72-4 | sc-296863 sc-296863A | 100 mg 1 g | $99.00 $599.00 | 1 | |
Zymosan is a glucan with repeating glucose units, which activates TLR2/6 heterodimers. Activation of TLR2/6 can indirectly enhance TLR1 activity by promoting the formation of TLR1/2 heterodimers, which are more responsive to their ligands. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
R-848 (Resiquimod) is a TLR7 and TLR8 agonist that stimulates the release of pro-inflammatory cytokines. This event can indirectly enhance TLR1 activity by increasing the expression of TLR1/2 heterodimers and their responsiveness to their ligands. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
Gardiquimod is a specific TLR7 agonist that stimulates the release of pro-inflammatory cytokines. This event can indirectly enhance TLR1 activity by increasing the expression of TLR1/2 heterodimers and their responsiveness to their ligands. | ||||||
Loxoribine | 121288-39-9 | sc-203118 sc-203118A | 25 mg 100 mg | $124.00 $390.00 | 1 | |
Loxoribine is a potent TLR7 agonist that stimulates the release of pro-inflammatory cytokines. This event can indirectly enhance TLR1 activity by increasing the expression of TLR1/2 heterodimers and their responsiveness to their ligands. | ||||||